Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment

Hamda Althawadi, Halema Alfarsi, Samaher Besbes, Shahsoltan Mirshahi, Elodie Ducros, Arash Rafii Tabrizi, Marc Pocard, Amu Therwath, Jeannette Soria, Massoud Mirshahi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The objective of this study was to evaluate the role of activated protein C (aPC), known to be a physiological anticoagulant, in ovarian cancer cell activation as well as in loss of clotting of cancer ascitic fluid. The effect of aPC on an ovarian cancer cell line (OVCAR-3) was tested in regards to i) cell migration and adhesion with the use of adhesion and wound healing assays as well as a droplet test; ii) protein phosphorylation, evaluated by cyto-ELISA; iii) cell cycle modification assessed by flow cytometric DNA quantification; and iv) anticoagulant activity evaluated by the prolongation of partial thromboplastin time (aPTT) of normal plasma in the presence or absence of aPC-treated ovarian cancer cells. In addition, the soluble endothelial protein C receptor (sEPCR) was quantified by ELISA in ascitic fluid of patients with ovarian cancer. Our results showed that in the OVCAR-3 aPC-induced cells i) an increase in cell migration was noted, which was inhibited when anti-endothelial protein C receptor (EPCR) was added to the culture medium and which may act via MEK-ERK and Rho-GTPase pathways; ii) an increase in threonine, and to a lesser extent tyrosine phosphorylation; iii) cell cycle activation (G1 to S/G2); and iv) a 2-3-fold prolongation of aPTT of normal plasma. In the peritoneal fluid, the sEPCR concentration was 71±23 ng/ml. In conclusion, free aPC binds to membrane EPCR in ovarian cancer cells and induces cell migration via MEK-ERK and Rho-GTPase pathways. This binding could also explain the loss of clotting of peritoneal fluids.

Original languageEnglish
Pages (from-to)603-609
Number of pages7
JournalOncology Reports
Volume34
Issue number2
DOIs
Publication statusPublished - 1 Aug 2015

Fingerprint

Cellular Microenvironment
Tumor Microenvironment
Protein C
Ovarian Neoplasms
Cell Movement
Up-Regulation
Ascitic Fluid
rho GTP-Binding Proteins
Mitogen-Activated Protein Kinase Kinases
Anticoagulants
Cell Cycle
Enzyme-Linked Immunosorbent Assay
Phosphorylation
Partial Thromboplastin Time
Threonine
Cell Adhesion
Wound Healing
Tyrosine
Culture Media
Membrane Proteins

Keywords

  • Cancer cell migration
  • Ovarian cancer
  • Partial thromboplastin time
  • Peritoneal fluid
  • Protein C receptor
  • Rho-GTPase pathway
  • Thrombosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment. / Althawadi, Hamda; Alfarsi, Halema; Besbes, Samaher; Mirshahi, Shahsoltan; Ducros, Elodie; Tabrizi, Arash Rafii; Pocard, Marc; Therwath, Amu; Soria, Jeannette; Mirshahi, Massoud.

In: Oncology Reports, Vol. 34, No. 2, 01.08.2015, p. 603-609.

Research output: Contribution to journalArticle

Althawadi, H, Alfarsi, H, Besbes, S, Mirshahi, S, Ducros, E, Tabrizi, AR, Pocard, M, Therwath, A, Soria, J & Mirshahi, M 2015, 'Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment', Oncology Reports, vol. 34, no. 2, pp. 603-609. https://doi.org/10.3892/or.2015.4061
Althawadi, Hamda ; Alfarsi, Halema ; Besbes, Samaher ; Mirshahi, Shahsoltan ; Ducros, Elodie ; Tabrizi, Arash Rafii ; Pocard, Marc ; Therwath, Amu ; Soria, Jeannette ; Mirshahi, Massoud. / Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment. In: Oncology Reports. 2015 ; Vol. 34, No. 2. pp. 603-609.
@article{98fc124a1edb46c7a0d4fef109e5a283,
title = "Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment",
abstract = "The objective of this study was to evaluate the role of activated protein C (aPC), known to be a physiological anticoagulant, in ovarian cancer cell activation as well as in loss of clotting of cancer ascitic fluid. The effect of aPC on an ovarian cancer cell line (OVCAR-3) was tested in regards to i) cell migration and adhesion with the use of adhesion and wound healing assays as well as a droplet test; ii) protein phosphorylation, evaluated by cyto-ELISA; iii) cell cycle modification assessed by flow cytometric DNA quantification; and iv) anticoagulant activity evaluated by the prolongation of partial thromboplastin time (aPTT) of normal plasma in the presence or absence of aPC-treated ovarian cancer cells. In addition, the soluble endothelial protein C receptor (sEPCR) was quantified by ELISA in ascitic fluid of patients with ovarian cancer. Our results showed that in the OVCAR-3 aPC-induced cells i) an increase in cell migration was noted, which was inhibited when anti-endothelial protein C receptor (EPCR) was added to the culture medium and which may act via MEK-ERK and Rho-GTPase pathways; ii) an increase in threonine, and to a lesser extent tyrosine phosphorylation; iii) cell cycle activation (G1 to S/G2); and iv) a 2-3-fold prolongation of aPTT of normal plasma. In the peritoneal fluid, the sEPCR concentration was 71±23 ng/ml. In conclusion, free aPC binds to membrane EPCR in ovarian cancer cells and induces cell migration via MEK-ERK and Rho-GTPase pathways. This binding could also explain the loss of clotting of peritoneal fluids.",
keywords = "Cancer cell migration, Ovarian cancer, Partial thromboplastin time, Peritoneal fluid, Protein C receptor, Rho-GTPase pathway, Thrombosis",
author = "Hamda Althawadi and Halema Alfarsi and Samaher Besbes and Shahsoltan Mirshahi and Elodie Ducros and Tabrizi, {Arash Rafii} and Marc Pocard and Amu Therwath and Jeannette Soria and Massoud Mirshahi",
year = "2015",
month = "8",
day = "1",
doi = "10.3892/or.2015.4061",
language = "English",
volume = "34",
pages = "603--609",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment

AU - Althawadi, Hamda

AU - Alfarsi, Halema

AU - Besbes, Samaher

AU - Mirshahi, Shahsoltan

AU - Ducros, Elodie

AU - Tabrizi, Arash Rafii

AU - Pocard, Marc

AU - Therwath, Amu

AU - Soria, Jeannette

AU - Mirshahi, Massoud

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The objective of this study was to evaluate the role of activated protein C (aPC), known to be a physiological anticoagulant, in ovarian cancer cell activation as well as in loss of clotting of cancer ascitic fluid. The effect of aPC on an ovarian cancer cell line (OVCAR-3) was tested in regards to i) cell migration and adhesion with the use of adhesion and wound healing assays as well as a droplet test; ii) protein phosphorylation, evaluated by cyto-ELISA; iii) cell cycle modification assessed by flow cytometric DNA quantification; and iv) anticoagulant activity evaluated by the prolongation of partial thromboplastin time (aPTT) of normal plasma in the presence or absence of aPC-treated ovarian cancer cells. In addition, the soluble endothelial protein C receptor (sEPCR) was quantified by ELISA in ascitic fluid of patients with ovarian cancer. Our results showed that in the OVCAR-3 aPC-induced cells i) an increase in cell migration was noted, which was inhibited when anti-endothelial protein C receptor (EPCR) was added to the culture medium and which may act via MEK-ERK and Rho-GTPase pathways; ii) an increase in threonine, and to a lesser extent tyrosine phosphorylation; iii) cell cycle activation (G1 to S/G2); and iv) a 2-3-fold prolongation of aPTT of normal plasma. In the peritoneal fluid, the sEPCR concentration was 71±23 ng/ml. In conclusion, free aPC binds to membrane EPCR in ovarian cancer cells and induces cell migration via MEK-ERK and Rho-GTPase pathways. This binding could also explain the loss of clotting of peritoneal fluids.

AB - The objective of this study was to evaluate the role of activated protein C (aPC), known to be a physiological anticoagulant, in ovarian cancer cell activation as well as in loss of clotting of cancer ascitic fluid. The effect of aPC on an ovarian cancer cell line (OVCAR-3) was tested in regards to i) cell migration and adhesion with the use of adhesion and wound healing assays as well as a droplet test; ii) protein phosphorylation, evaluated by cyto-ELISA; iii) cell cycle modification assessed by flow cytometric DNA quantification; and iv) anticoagulant activity evaluated by the prolongation of partial thromboplastin time (aPTT) of normal plasma in the presence or absence of aPC-treated ovarian cancer cells. In addition, the soluble endothelial protein C receptor (sEPCR) was quantified by ELISA in ascitic fluid of patients with ovarian cancer. Our results showed that in the OVCAR-3 aPC-induced cells i) an increase in cell migration was noted, which was inhibited when anti-endothelial protein C receptor (EPCR) was added to the culture medium and which may act via MEK-ERK and Rho-GTPase pathways; ii) an increase in threonine, and to a lesser extent tyrosine phosphorylation; iii) cell cycle activation (G1 to S/G2); and iv) a 2-3-fold prolongation of aPTT of normal plasma. In the peritoneal fluid, the sEPCR concentration was 71±23 ng/ml. In conclusion, free aPC binds to membrane EPCR in ovarian cancer cells and induces cell migration via MEK-ERK and Rho-GTPase pathways. This binding could also explain the loss of clotting of peritoneal fluids.

KW - Cancer cell migration

KW - Ovarian cancer

KW - Partial thromboplastin time

KW - Peritoneal fluid

KW - Protein C receptor

KW - Rho-GTPase pathway

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84931401339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931401339&partnerID=8YFLogxK

U2 - 10.3892/or.2015.4061

DO - 10.3892/or.2015.4061

M3 - Article

VL - 34

SP - 603

EP - 609

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -